MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 157 filers reported holding MERSANA THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $82,591 | -35.0% | 65,032 | +68.4% | 0.00% | – |
| Q2 2023 | $127,047 | -5.8% | 38,616 | +17.7% | 0.00% | – |
| Q1 2023 | $134,853 | -30.8% | 32,811 | -1.4% | 0.00% | – |
| Q4 2022 | $194,980 | -94.9% | 33,273 | -94.1% | 0.00% | -100.0% |
| Q3 2022 | $3,795,000 | +2711.1% | 561,274 | +1822.8% | 0.00% | – |
| Q2 2022 | $135,000 | +12.5% | 29,190 | -2.9% | 0.00% | – |
| Q1 2022 | $120,000 | -35.1% | 30,068 | +1.2% | 0.00% | – |
| Q4 2021 | $185,000 | -38.9% | 29,718 | -7.7% | 0.00% | – |
| Q3 2021 | $303,000 | -17.7% | 32,211 | +19.1% | 0.00% | – |
| Q2 2021 | $368,000 | -94.5% | 27,045 | -93.4% | 0.00% | -100.0% |
| Q1 2021 | $6,670,000 | -81.2% | 412,170 | -69.0% | 0.00% | -80.0% |
| Q4 2020 | $35,407,000 | +70.2% | 1,330,589 | +19.1% | 0.01% | +42.9% |
| Q3 2020 | $20,806,000 | -9.5% | 1,117,416 | +13.7% | 0.01% | -12.5% |
| Q2 2020 | $22,998,000 | – | 982,795 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 4,005,600 | $64,810,000 | 6.21% |
| Bain Capital Life Sciences Investors, LLC | 3,695,667 | $59,796,000 | 3.39% |
| COMMODORE CAPITAL LP | 429,228 | $6,945,000 | 2.77% |
| ACUTA CAPITAL PARTNERS, LLC | 357,689 | $5,787,000 | 2.09% |
| Avoro Capital Advisors LLC | 6,800,000 | $110,024,000 | 1.90% |
| Ghost Tree Capital, LLC | 450,000 | $7,281,000 | 1.71% |
| RHO CAPITAL PARTNERS INC | 796,458 | $12,887,000 | 1.24% |
| Rock Springs Capital Management LP | 2,775,127 | $44,902,000 | 0.98% |
| Sio Capital Management, LLC | 157,259 | $2,544,000 | 0.52% |
| Bellevue Group AG | 2,850,010 | $46,113,000 | 0.49% |